Share on StockTwits

The Medicines Company (NASDAQ:MDCO) is scheduled to be releasing its Q214 earnings data on Wednesday, July 23rd. Analysts expect The Medicines Company to post earnings of ($0.02) per share and revenue of $183.75 million for the quarter. Persons that are interested in registering for the company’s earnings conference call can do so using this link.

The Medicines Company (NASDAQ:MDCO) last released its earnings data on Wednesday, April 23rd. The company reported ($0.08) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.07) by $0.01. The company had revenue of $177.20 million for the quarter, compared to the consensus estimate of $175.60 million. During the same quarter in the previous year, the company posted ($0.21) earnings per share. The company’s revenue for the quarter was up 13.7% on a year-over-year basis. On average, analysts expect The Medicines Company to post $-0.16 EPS for the current fiscal year and $1.44 EPS for the next fiscal year.

Shares of The Medicines Company (NASDAQ:MDCO) opened at 26.14 on Tuesday. The Medicines Company has a 52-week low of $23.53 and a 52-week high of $41.28. The stock’s 50-day moving average is $28.09 and its 200-day moving average is $29.60. The company has a market cap of $1.677 billion and a P/E ratio of 77.08.

On a related note, analysts at Zacks reiterated a “neutral” rating on shares of The Medicines Company in a research note on Friday, May 30th. They now have a $29.00 price target on the stock. Six analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus target price of $33.00.

The Medicines Company, is a pharmaceutical company focused on the treatment of critical care patients through the delivery of medicines to the global hospital marketplace.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.